Skip to content
value.today
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc.

Total raised
$493 M
1 round on record
Latest round
$493 M
Mar 2020
First round on record
Mar 2020
Today
Went public
See the company page

Lyell Immunopharma, Inc. is listed today as Lyell Immunopharma, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Lyell Immunopharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2020$493 MNo. 1$250 million to $1 billion

Lyell Immunopharma, Inc.: Raise no. 1, Mar 2020

Investors in this round

10 investors had bought by the notice of Mar 20, 2020: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Lyell Immunopharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$493 M of $493 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: "Sale and issuance of Series C Preferred Stock (""Series C"") and the underlying shares of Common Stock issuable upon conversion of Series C."
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Elizabeth Homans · Executive Officer
  • Heather Turner · Executive Officer
  • Margo Roberts · Executive Officer
  • Nicholas Restifo · Executive Officer
  • Richard Goold · Executive Officer
  • Richard Klausner · Executive Officer, Director, Promoter
  • Stan Riddell · Executive Officer
  • Stephen Hill · Executive Officer
  • Catherine Friedman · Director
  • Hans Bishop · Director
  • Robert Nelson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Heather Turner, Secretary. Source: SEC Form D, newest notice filed Mar 20, 2020. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Lyell Immunopharma, Inc., its revenue in fiscal 2025 came from these business segments: Reportable segment $40,000 (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Lyell Immunopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).

    SEC Form D · Mar 2020

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2020

Products and services#

No products or services of Lyell Immunopharma, Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Lyell Immunopharma, Inc.
InvestorKindAmountRoundRoleSource
ARCH Venture Fund IX, L.P.Venture capitalnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Fund IX Overage, L.P.Venture capitalnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners IX, LLCVenture capitalnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners IX, L.P.Venture capitalnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
ARCH Venture Partners IX Overage, L.P.Venture capitalnot statednot statedHeld Series A and C preferred stock, 10% owner (Form 3, 2021)SEC Form 3
GSK PLCFund or asset managernot statednot statedHeld Series AA preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Hans Edgar BishopPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 10 investors.

Largest shareholders today

Institutions holding Lyell Immunopharma, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Lyell Immunopharma, Inc.
NameRoleNamed in
Elizabeth HomansExecutive officerMar 2020
Heather TurnerExecutive officerMar 2020
Margo RobertsExecutive officerMar 2020
Nicholas RestifoExecutive officerMar 2020
Richard GooldExecutive officerMar 2020
Richard KlausnerExecutive officerMar 2020
Stan RiddellExecutive officerMar 2020
Stephen HillExecutive officerMar 2020
Catherine FriedmanDirectorMar 2020
Hans BishopDirectorMar 2020
Richard KlausnerDirectorMar 2020
Robert NelsonDirectorMar 2020
Richard KlausnerPromoterMar 2020

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.